Sunday, October 23, 2011

ECTRIMS: Novel MS Drug Likely to Survive Missed Endpoint (CME/CE)

AMSTERDAM (MedPage Today) -- With one exception, the investigational oral drug laquinimod was more effective than placebo, and possibly better than interferon-beta-1a (Avonex), in reducing clinically relevant aspects of multiple sclerosis, a researcher said here.





No comments:

Post a Comment